Abstract
Pyrimidine diseases result from deficiencies in pyrimidine de novo synthesis, degradation, and salvage pathways. Enzymatic deficiencies in pyrimidine catabolism lead to mitochondrial neurogastrointestinal encephalopathy (MNGIE), pyrimidinuria, dihydropyrimidinuria, ureidopropionic aciduria, and other disorders. While MNGIE presents with gastrointestinal dysmotility, cachexia, and leukoencephalopathy, pyrimidinuria and dihydropyrimidinuria may show symptoms of epilepsy, autism, mental retardation, and dysmorphic features. The application of HPLC-MS/MS facilitates rapid screening of pyrimidine metabolites. Here we describe an LCMS method for determination of uracil, thymine, thymidine, dihydrouracil, and dihydrothymine that are diagnostic biomarkers of MNGIE, pyrimidinuria, and dihydropyrimidinuria.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Nyhan WL (2005) Disorders of purine and pyrimidine metabolism. Mol Genet Metab 86(1–2):25–33
Jurecka A (2009) Inborn errors of purine and pyrimidine metabolism. J Inherit Metab Dis 32(2):247–263
Balasubramaniam S, Duley JA, Christodoulou J (2014) Inborn errors of pyrimidine metabolism: clinical update and therapy. J Inherit Metab Dis 37(5):687–698
Kelley RE, Andersson HC (2014) Disorders of purines and pyrimidines. Handb Clin Neurol 120:827–838
van Gennip AH, Bierau H, Nyhan WL (2006) Inborn error of purine and pyrimidine metabolism. In: Blau N, Hoffman G, Leonard J (eds) Physician’s guide to the treatment and follow-up of metabolic diseases. Springer-Verlag, Berlin, Heidelberg, pp 245–255
van den Berghe G, Vencent M-F, Marie S (2012) Disorders of purine and pyrimidine metabolism. In: Saudubray JM, van den Berghe G, Walter JH (eds) Inborn metabolic diseases diagnosis and treatment. Springer-Verlag, Berlin, Heidelberg, pp 499–518
van Kuilenburg ABP, van Cruchten A, Aberling NGGM (2008) Screening for disorders of purine and pyrimidine metabolism using HPLC-electrospray tandem mass spectrometry. In: Blau N, Duran M, Gibson KM (eds) Laboratory guide to the methods in biochemical genetics. Springer-Verlag, Berlin, Heidelberg, pp 725–737
van Kuilenburg AB, Dobritzsch D, Meijer J, Meinsma R, Benoist JF, Assmann B, Schubert S, Hoffmann GF, Duran M, de Vries MC, Kurlemann G, Eyskens FJ, Greed L, Sass JO, Schwab KO, Sewell AC, Walter J, Hahn A, Zoetekouw L, Ribes A, Lind S, Hennekam RC (2010) Dihydropyrimidinase deficiency: phenotype, genotype and structural consequences in 17 patients. Biochim Biophys Acta 1802(7–8):639–648
van Kuilenburg AB, Meijer J, Dobritzsch D, Meinsma R, Duran M, Lohkamp B, Zoetekouw L, Abeling NG, van Tinteren HL, Bosch AM (2007) Clinical, biochemical and genetic findings in two siblings with a dihydropyrimidinase deficiency. Mol Genet Metab 91(2):157–164
Burton K (ed) (1974) Spectral data and pK values for purines, pyrimidines, nucleosides, and nucleotides. Data for biochemical research. Oxford University Press, London
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Sun, Q. (2016). Urine Pyrimidine Metabolite Determination by HPLC Tandem Mass Spectrometry. In: Garg, U. (eds) Clinical Applications of Mass Spectrometry in Biomolecular Analysis. Methods in Molecular Biology, vol 1378. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3182-8_25
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3182-8_25
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3181-1
Online ISBN: 978-1-4939-3182-8
eBook Packages: Springer Protocols